Sherwin-Williams (SHW) Q4 2025 earnings review
Acquisition Masks Organic Weakness; 2026 Outlook Stalls
Sherwin-Williams reported Q4 revenue growth of 5.6%, nominally accelerating from Q3. However, this was entirely driven by the acquisition of Suvinil (contributed 3.1% to consolidated growth). Organic demand remains lackluster: Paint Stores Group (PSG) same-store sales decelerated to 1.0%, and Consumer Brands (CBG) organic sales declined. While management praises 'record' full-year results, the 2026 guidance is sobering: Adjusted EPS of $11.50-$11.90 implies only ~2.4% growth at the midpoint, signaling that the 'softer for longer' demand environment is capping earnings expansion.
🐂 Bull Case
The company generated $3.45 billion in net operating cash for FY25 (14.6% of sales). This strong conversion supported $2.4 billion in shareholder returns (buybacks + dividends) and a 47th consecutive year of dividend increases.
PCG margins expanded 50bps YoY to 14.9% (Adjusted: 19.0%), and sales grew 3.3%. The segment effectively managed costs despite flat organic volumes.
🐻 Bear Case
While CBG sales rose 24.5% due to the Suvinil acquisition, organic volume was negative. Suvinil contributed 24.8% to growth, implying the legacy business contracted slightly due to continued North American DIY softness.
The crown jewel segment, PSG, saw same-store sales growth slow to +1.0% in Q4 from +3.6% in Q3. This indicates pricing power may be plateauing while volumes remain under pressure.
⚖️ Verdict: ⚪
Neutral. The Suvinil acquisition provides a headline revenue boost, but organic fundamentals are deteriorating. With 2026 earnings guidance implying barely 2% growth, the premium valuation relies heavily on a housing market turnkey that hasn't arrived yet.
Key Themes
Consumer Brands Margin Compression
A significant red flag in Q4. Despite the revenue boost from Suvinil, CBG segment profit fell 15.6%. Reported margin collapsed to 6.8% from 10.1% a year ago. Management cited restructuring actions and acquisition costs, but even Adjusted Segment Margin (10.6%) contracted 180bps YoY.
Suvinil Acquisition Impact
The acquisition of Suvinil (closed Oct 1, 2025) contributed $164.5 million to Q4 sales. While it successfully diversified revenue, it is currently dilutive to margins (see CBG concern) and added interest expense. The integration execution in 2026 will be critical to determine if this was a value-add purchase.
Pricing Power Maintaining Margins
Despite choppy demand, consolidated gross margin remained stable at 48.5% (vs 48.6% LY). In the Paint Stores Group, sales increased 2.7% primarily due to price increases (mid-single digit impact), which offset a low-single digit decrease in volume. This confirms SHW retains pricing power, though volume loss is a growing concern.
Persistent Demand Weakness
Management reiterated the 'softer-for-longer' narrative. PSG volume declined low-single digits. Core North America DIY demand remains soft. The guidance for Q1 2026 (up mid-single digit sales) relies heavily on the inorganic contribution from Suvinil rather than organic volume recovery.
Restructuring Acceleration
Q4 saw continued restructuring charges, particularly in CBG ($15.6M). The company is actively rightsizing costs to align with lower volumes, which supported Adjusted EBITDA growth (+11% YoY) despite flat net income.
Other KPIs
Decelerating. Dropped from +3.6% in Q3 and +2.0% in the prior year period. This suggests the organic growth engine is sputtering as transaction volumes remain negative.
Stable/Strong. Increased 9% YoY. Represents 14.6% of Net Sales. This remains a bright spot, allowing continued aggressive capital returns despite earnings stagnation.
Increasing. Corporate expenses rose 8.7% YoY in Q4 (from $286.4M), outpacing revenue growth. Attributed to new headquarters costs and R&D building expenses.
Guidance
Stable/Slow Growth. The midpoint ($11.70) represents only a 2.4% increase over FY 2025's $11.43. This is a significant deceleration from the historical double-digit growth algorithm investors expect.
Stable. Considering Suvinil contributes inorganic growth for the first 9 months of 2026, this guidance implies organic sales will likely remain flat to slightly up at best.
Accelerating vs Q1 2025 (-1.1%), but primarily due to the Suvinil acquisition overlap. Underlying demand remains 'softer-for-longer'.
Key Questions
Organic Volume Trajectory
With PSG same-store sales decelerating to 1.0% in Q4 and price contributing 'mid-single digits,' implied volume is negative. When does management expect volume to turn positive in 2026?
Consumer Brands Margins
CBG margins collapsed to 6.8% in Q4. How much of this is structural vs. one-time restructuring/acquisition costs, and what is the bridge to return to double-digit margins in 2026?
Suvinil Contribution vs Dilution
Suvinil added 24.8% to CBG sales but seems to be a drag on earnings given the profit decline. What is the accretive timeline for this acquisition?
New Headquarters Cost Impact
Administrative costs rose significantly in Q4. How much incremental expense related to the new HQ is embedded in the 2026 guidance?